RUBY
Closed
Rubius Therapeutics Inc
0.057
+0.002 (+3.60%)
Last Update: 29 Dec 2023 23:49:00
Yesterday: 0.0555
Day's Range: 0.055 - 0.057
Send
sign up or login to leave a comment!
When Written:
0.0205
Rubius Therapeutics Inc is a biotechnology company headquartered in Cambridge, Massachusetts. The company was founded in 2013 with the goal of developing a new class of cellular therapies that harness the power of red blood cells to create a platform for the treatment of a wide range of diseases. The company's proprietary platform technology, called RED PLATFORM, enables the creation of Red Cell Therapeutics (RCTs), which are designed to mimic the natural function of red blood cells in the body.
Rubius is focused on developing RCTs for the treatment of rare diseases, cancer, and autoimmune disorders. The company's lead product candidate, RTX-240, is being developed for the treatment of solid tumors and hematological malignancies. The company is also developing RCTs for the treatment of phenylketonuria (PKU), a rare genetic disorder, and sickle cell disease.
Rubius went public in July 2018 and is traded on the NASDAQ under the ticker symbol RUBY. The company has collaborations with several pharmaceutical companies, including Sanofi and Eli Lilly, and has raised over $500 million in funding to date.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Rubius is focused on developing RCTs for the treatment of rare diseases, cancer, and autoimmune disorders. The company's lead product candidate, RTX-240, is being developed for the treatment of solid tumors and hematological malignancies. The company is also developing RCTs for the treatment of phenylketonuria (PKU), a rare genetic disorder, and sickle cell disease.
Rubius went public in July 2018 and is traded on the NASDAQ under the ticker symbol RUBY. The company has collaborations with several pharmaceutical companies, including Sanofi and Eli Lilly, and has raised over $500 million in funding to date.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








